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tion on hospital care was only collected for one season.
More individualised estimates of hospitalisation costs
may be obtained with patient characteristics such as ges-
tational age and presence of BPD.
PIN22
PHARMACOECONOMIC EVALUATION OF
STREPTOMYCIN VERSUS ETHAMBUTOL AS
PRIMARY ANTITUBERCULAR DRUGS IN LAGOS
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Available resources are very for this research is limited,
hence the need to be cost conscious. OBJECTIVES: The
purpose of the research was to know which of the two
antitubercular drugs (both of which are still actively used
in Nigeria) is more cost effective in phase I treatment 
of tuberculosis and to inﬂuence decision making.
METHOD: Cost Effectiveness Analysis was the applied
tool for these methods, and the prescribed/dispensed anti-
tubercular drugs between 1997 and 1999 were reviewed
retrospectively. Relevant information such as diagnosis,
prescribed/dispensed drugs, dosage, duration of therapy,
physician’s remarks, and cost were obtained from patient
case notes and dispensed prescriptions. These were used
in conjunction with time and motion studies and standard
cost accounting technique. The cost per deﬁned daily
dosage (DDD) was calculated, and the costs of drug/
disposables acquisition and overhead costs were included
in the analysis. The literature was reviewed for positive
and negative consequences of the considered options.
Outcome measure of effectiveness was improved in signs
and symptoms of tuberculosis/eradication of Mycobac-
terium. A decision table was used to arrive at the effec-
tiveness rating, which was compared using chi sqaure
analysis. RESULTS: The analysis showed that ethambu-
tol tab is more cost effective than streptomycin inj, which
is still widely in use. The cost/DDD of ethambutol was
N4.00/unit effectiveness while that of Streptomycin was
N65.00/unit of effectiveness. The decision did not change
when some variables were altered in favour of strepto-
mycin inj. (the less cost effective option). Increasing the
cost of ethambutol by several folds, increased the effec-
tiveness rating of streptomycin to that of ethambutol etc.,
which did not change the conclusion. CONCLUSION:
Streptomycin inj. should no longer be considered as a
primary drug in the treatment of tuberculosis, which is
still very common in Nigeria. However, the various con-
traindications/side effects of ethambutol such as optic
neuritis need to be monitored for in patient. Economic
evaluation of therapy is necessary to avoid trading-off of
more cost effective therapeutic options.
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The use of economic analysis is increasingly advocated by
funding agencies to acheive efﬁcient cost containment
strategy. OBJECTIVES: To inform the use of antibacteri-
als in chosen hospitals and to propose inclusion of eco-
nomic evaluation of drug therapy in policy formulation
and decision-making. METHODS: Cost Minimisation
Analysis; the most applicable tool for generic equivalent
drugs was used. This was compared in three health insti-
tutions. These include a tertiary, Lagos University Teach-
ing Hospital (LUTH); a secondary, General Hospital
Lagos (GHL); and a primary, Health Centre Harvey
Road, Yaba (HCHR), as well as a community pharmacy
outlet for prescriptions of GHL. Relevant information
such as diagnosis, cost of drugs, dosage, duration of
therapy among others were obtained from patient case
notes for which antibacterials are the mainstay of therapy
and dispensed prescriptions. The mean cost per deﬁned
daily dosage (DDD) of generic and branded for each
antibacterial was computed for the various hospitals.
These were compared using student ‘t’ test. The outcome
measure was erradication of bacterial in question by the
respective antibacterials. RESULTS: The use of more
expensive branded drugs is very rampant even when the
generic equivalence is available. The difference in their
cost/DDD is very signiﬁcant (P < 0.05; n = 1,576 in
LUTH, n = 1,200 in GHL, n = 900 in HCHR, n = 750
in the community pharmacy). For example, in LUTH, 
the cost/DDD of ciproﬂoxacin was N310 for branded
product and N160 for generic. Also observed were some
irrational combinations especially in the primary health
centre. CONCLUSION: A form of economic evaluation
of drug therapy is necessary for health policy and deci-
sion makers to be more informed on cost implication 
of their choices and trade-offs. Systematic appraisal of
available options needs to be well understood in view of
limited resources. Appropriate and timely intervention 
for sustainable improvement is mandatory for costs to be
greatly minimised.
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OBJECTIVES: To evaluate the impact of an inﬂuenza
vaccination campaign: decrease of attack rates of
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inﬂuenza-like-illness (ILI), work productivity and 
indirect costs (potential cost savings) for the em-
ployer. METHODS: A prospective observational study
was conducted among the workforce of a bank of Bogota
from October 2000 to May 2001, with 2 cohorts:
inﬂuenza vaccinated (volunteers) and not vaccinated. Self-
administered monthly questionnaires collected socio-
economic and health status information, data on ILI
symptoms and sick leaves. Vaccine’s adverse events were
reported one week after injection. Cost-beneﬁt analyses
were performed from the employer perspective using indi-
vidual operating income and salary values. Costs of vac-
cination included vaccine administration and adverse
events. Loss of productivity was assessed by sick leave
days, days of reduced effectiveness at work due to being
not well because of ILI. RESULTS: Among the 759 sub-
jects, 56% vaccinated and 44% not vaccinated, the attack
rates of ILI were respectively 15% versus 47%, with pres-
ence of usual symptoms (cough, chills, muscle aches . . .)
and fever in 93% of the reported ILI. Absence rates for
ILI were similar in the 2 cohorts: 2.6%, with a mean of
3.1 days of sick leave, as well as the proportions of people
feeling not well because of ILI: 93%, with a mean of 4
days before being well again. Using the realistic hypoth-
esis of a reduced effectiveness of 30% when the patient
is not well because of ILI, global cost savings were
US$7469 for the study population and US$59 per indi-
vidual i.e. a cost-beneﬁt ratio of 20%. CONCLUSIONS:
Among the studied volunteers, ILI has signiﬁcant impact
on work productivity, in terms of indirect costs, even if
considering lower work effectiveness rates’ hypotheses, in
conditions of mild outbreak of inﬂuenza. Possible expan-
sion of inﬂuenza vaccination to all the company could
lead to important employer cost savings.
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OBJECTIVE: In healthy working adults, it has been doc-
umented that vaccination programs may yield cost-
savings by avoiding absenteeism and loss of productivity.
However few studies provide an international perspec-
tive. The objective of this project is to develop a multi-
national measurement of the cost-beneﬁt aspect of
vaccination programs against inﬂuenza, typhoid fever and
hepatitis A in an adult population working in various
countries and industrial sectors. METHODS: A cost-
beneﬁt model has been developed in order to calculate the
cost-beneﬁt result of vaccination programs. The costs of
the vaccination alternative, including associated immu-
nization services are thus compared to the beneﬁts i.e.
avoided absenteeism and loss of productivity by prevent-
ing the diseases. Those beneﬁts are represented by three
different items being 1) Avoided loss of labor costs; 2)
Avoided cost of replacement; and 3) Avoided loss of oper-
ating income. Companies published ﬁnancial data from
four countries (Australia, Turkey, Brazil and Philippines)
have been sampled and gathered in order to yield an
average cost-beneﬁt result by country. A sensitivity analy-
sis and break-even analysis have been performed on the
main criteria involved in the calculation. RESULTS:
Considering the three diseases, the results obtained 
show an average cost of diseases for 100 employees 
of US$11,086.81 per year. The net cost-savings per
employee vaccinated and per year ranged from US$13.54
(in the Philippines) to US$80.17 (in Turkey). CONCLU-
SION: This predictive approach aimed at assessing the
return on investment for companies in case of funding a
vaccination program proposed to the employees. The 
simulations based on aggregated published ﬁnancial data
show a cost-savings speciﬁc to each country for different
industrial sectors. It deserves further analysis on a larger
sample of companies in other countries and industrial
sectors.
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OBJECTIVES: In developing and transitional countries,
poor injection practices transmit potentially life-
threatening pathogens. We modelled the cost effectiveness
of safe and appropriate use of injections policies in terms
of cost per Disability Adjusted Life Year (DALY) pre-
vented. METHODS: A mass action model estimated the
incidence of injection-associated Hepatitis B Virus (HBV),
Hepatitis C Virus (HCV) and Human Immunodeﬁciency
Virus (HIV) infections. We reviewed the effectiveness of
interventions to reduce injection overuse or unsafe prac-
tices. DALYs were age-adjusted and 3% discounted. We
quantiﬁed the resources needed to implement effective
interventions and estimated their cost by region. The cost
effectiveness compared the effects of a “Do nothing” sce-
nario with that of an intervention on a theoretical 2000
cohort using WHO Global Burden of Disease regions and
a 30-year analytic horizon. RESULTS: Preliminary results
suggest that worldwide, re-use of injection equipment in
2000 accounted for 32%, 40% and 5% of new HBV,
HCV and HIV infections respectively, causing the loss 
of 9,177,679 DALYs between 2000 and 2030. Interven-
tions in 2000 for the safe (provision of single-use sy-
ringes, average effectiveness: 95%) and appropriate 
use (patients-providers interactional group discussions,
average effectiveness: 30%) would prevent 8,856,460
DALYs and cost US$463.4 million (range by region of the
cost per DALY prevented: 6.7–1652). Compared to other
regions, the cost per DALY prevented was lower in
